|
 Lechleiter joined Lilly in 1979 as a senior organic chemist, and
became the CEO in April 2008.
Lilly on Tuesday reported better-than-expected quarterly sales,
fueled by newer drugs, and predicted average annual revenue growth
of at least 5 percent through the end of the decade due to its
growing roster of medicines.
The Indianapolis drugmaker's earnings growth resumed last year after
three years of tumbling sales caused by competition from generic
drugs.
(Reporting by Natalie Grover in Bengaluru; Editing by Sriraj
Kalluvila)
[© 2016 Thomson Reuters. All rights
reserved.] Copyright 2016 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed. |
